Abstract 2830: Fluoxetine mediate radiosensitivity and inhibit metastasis of osteosarcoma cells via RANK/RANKL signaling

Abstract

Abstract Osteosarcoma (OS) is most common primary malignant bone tumour OS was flagrantly byaffecting pediatric and young adolescents patients with its outrageous metastatic rate and poorprognosis. It was aggressive in local invasion and further metastasis, especially pulmonarymetastasis. Radiotherapy (RT) was a clinical treatment method that using high-energy ionizingradiation to control tumour growth with low risk and considerably successful rate.Contradictorily, OS was recognized as radio-resistant tumour. Meanwhile, majority of OScases were diagnosed suffering depression and influence patient’s conditions critically. Hence,aim of this prospective study was to identify that combinational therapeutic efficacy ofradiation therapy and fluoxetine (Prozac) through mediating radiosensitivity and inhibitmetastasis of OS cells via RANK/RANKL signaling. OS cell lines U2OS and MG63 were usedin this study. To investigate the cells survival fraction, clonogenic assay were performed. Next,to examine metastasis and invasions of cells wound healing assay and transwell assay werecarried out. Furthermore, TUNEL assay was used to evaluate DNA damage of OS cells.Fluoxetine effectively inhibited the metastasis and invasion ability of OS cells. Thecombinational therapy of fluoxetine and RT successfully decreased the surviving fraction ofOS cells and induced the damage of DNA. Additionally, the protein expression ofRANK/RANKL was markedly suppressed by fluoxetine as illustrated by Western blottingassay. In sum, the combination treatment of radiotherapy with the interrelation of fluoxetinewas showing its potential and consider as new treatment strategy might elevate treatmentefficacy for OS. Keywords: Osteosarcoma (OS), Radiotherapy (RT), Fluoxetine, RANK/RANKL Citation Format: Peggy Tan, Jai-Jen Tsai, Fei-Ting Hsu, Yu-Chiang Liu. Fluoxetine mediate radiosensitivity and inhibit metastasis of osteosarcoma cells via RANK/RANKL signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2830.